10261-82-2

Basic information

• Product Name: 2-Hydroxy-1,5-naphthyridine
• Synonyms: 2-Hydroxy-1,5-naphthyridine;1,5-Naphthyridin-2(1H)-one;1,5-naphthyridin-2-ol;1,5-Naphthyridin-2(1H)
• CAS NO: 10261-82-2
• Molecular Formula: C₈H₆N₂O
• Molecular Weight: 146.14604
• Mol File: 10261-82-2.mol

Chemical Properties

• Melting Point: 258 °C
• Boiling Point: 391.8 °C at 760 mmHg
• Flash Point: 190.8 °C
• Appearance: /
• Density: 1.267g/cm³
• Vapor Pressure: 2.4E-06mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.29±0.20(Predicted)
• CAS DataBase Reference: 2-Hydroxy-1,5-naphthyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hydroxy-1,5-naphthyridine(10261-82-2)
• EPA Substance Registry System: 2-Hydroxy-1,5-naphthyridine(10261-82-2)

Safety Data

• Hazardous Substances Data: 10261-82-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Hydroxy-1,5-naphthyridine is used as a reactant in the design of brain penetrant JNK inhibitors for the prevention of neurodegeneration. Its unique structure allows it to cross the blood-brain barrier, making it a promising candidate for the development of drugs targeting neurodegenerative diseases such as Alzheimer's and Parkinson's. By inhibiting the c-Jun N-terminal kinase (JNK) pathway, these inhibitors can potentially protect neurons from damage and slow down the progression of these debilitating conditions.

InChI:InChI=1/C8H6N2O/c11-8-4-3-6-7(10-8)2-1-5-9-6/h1-5H,(H,10,11)

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 6298-19-7 2-chloro-3-aminopyridine 
• 141-32-2 acrylic acid n-butyl ester 
• 881658-92-0 8-bromo-2-methoxy-1,5-naphthyridine 
• 23443-25-6 6-methoxy-1,5-naphthyridin-4-ol 
• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 56-81-5 glycerol 
• 7664-93-9 sulfuric acid 
• 33630-94-3 5-amino-2-hydroxypyridine 
• 7778-39-4 orthoarsenic acid 
• 1452561-63-5 (E)-methyl 3-(3-aminopyridin-2-yl)acrylate 
• 27017-69-2 2-methoxy-[1,5]-naphthyridine 
• 60058-16-4 4-hydroxy-1H-[1,5]naphthyridin-2-one 
• 28252-82-6 2,4-dichloro-1,5-naphthyridine 

Downstream Products

• 1309774-03-5 7-bromo-2-chloro-1,5-naphthyridine 
• 1422123-35-0 C₂₁H₂₂N₄O₃ 
• 1422123-99-6 C₂₂H₂₂N₆O 
• 1422124-32-0 C₂₁H₂₀N₆O 
• 1422124-72-8 C₂₁H₂₁N₅O₂ 
• 1422125-49-2 C₂₄H₂₅N₇O₄S 
• 1422125-93-6 C₂₂H₂₃N₇O 
• 1173896-38-2 1-(2-(4-((3,4-dichlorobenzyl)amino)piperidin-1-yl)ethyl)-1,5-naphthyridin-2(1H)-one 
• 959615-84-0 2-(2-oxo-1,5-naphthyridin-1(2H)-yl)acetaldehyde 
• 1173897-77-2 C₁₁H₁₂N₂O₃ 
• 1422125-94-7 N-((7-(1-methyl-1H-pyrazol-4-yl)-1,5-naphthyridin-2-yl)carbamothioyl)benzamide 
• 7689-62-5 2-chloro-1,5-naphthyridine 

Relevant articles and documents

Design and synthesis of brain penetrant selective JNK inhibitors with improved pharmacokinetic properties for the prevention of neurodegeneration

The SAR of a series of brain penetrant, trisubstituted thiophene based JNK inhibitors with improved pharmacokinetic properties is described. These compounds were designed based on information derived from metabolite identification studies which led to compounds such as 42 with lower clearance, greater brain exposure and longer half life compared to earlier analogs.

NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

2-hydroxy-1,5-naphthyridine preparation method

The invention relates to the field of chemistry, in particular to a medicinal and chemical intermediate 2-hydroxy-1,5-naphthyridine preparation method. The preparation method includes steps: (1) adding 2-chloro-5-aminopyridine into a sulfuric acid solution, adding an oxidizing agent and a buffering agent under a condition of stirring to obtain a reaction liquid A; (2) dropwise adding glycerin into the reaction liquid A obtained at the step (1), keeping the temperature for 2h, cooling to the room temperature, and adding a solvent to perform dispersion to obtain a reaction liquid B; (3) adding alkaline substances into the reaction liquid B to realize neutralization, and leaching to obtain filter residues; (4) adding a solvent into the filter residues obtained at the step (3), stirring, and leaching to obtain an organic phase; (5) concentrating the organic phase obtained at the step (4), cooling, and leaching to obtain 2-hydroxy-1,5-naphthyridine.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF

A compound represented by Formula [1] (in the formula, Z1 represents N, CH, or the like; X1 represents NH or the like; R1 represents a heteroaryl group or the like; each of R2, R3, and R4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R5 represents a heteroaryl group or the like) or salt thereof.

1,5-NAPHTHYRIDINE DERIVATIVE OR SALT THEREOF

A 1,5-naphthyridine derivative represented by Formula [1] (in which R1, R2, R3, R4 and R5 represent a hydrogen atom, -L-Z (in which Z represents a non-aromatic heterocyclic group or the like; and L re

HETEROBICYCLIC COMPOUNDS

Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

NAPHTHYRIDIN-2 (1 H)-ONE COMPOUNDS USEFUL AS ANTIBACTERIALS

Compounds of Formula (I) wherein substituents R1, R2 and R5 are as defined, and Ar represents substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, furanyl, imidazolyl and thiophenyl substituted by a hydroxyalkyl substituent and an optional other substituent; compositions containing them, their use in therapy, including their use as antibacterials, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

Condensed Heteroaromatic Ring Systems. IV. Synthesis of Naphthyridine Derivatives by Cyclization of Aminopyridineacrylic Esters

The reaction of aminohalopyridines with ethyl acrylate in the presence of palladium(II)acetate and triarylphosphine gave ethyl aminopyridineacrylates.The cyclization of the resulting acrylates under basic conditions gave naphthyridinones having a carbostyril-type moiety.Keywords- intramolecular cyclization; palladium catalyst; ethyl acrylate; naphthyridinone; pyridineacrylic ester